title: Pharmacogenetics of topical and systemic treatment of psoriasis.
abstract: Psoriasis is a chronic inflammatory skin disease. The cause of psoriasis is unknown, although genetics may play a key role in its development. Treatment of the disease varies with severity. Topical drugs, such as corticosteroids, coal tar, retinoids and vitamin D analogs, are commonly used to treat mild psoriasis. Phototherapy and systemic drugs, such as calcineurin inhibitors, methotrexate, acitretin and biological drugs, are usually used to treat moderate-to-severe psoriasis. Not all patients respond well to treatment, and some can develop severe adverse effects. Interindividual differences in several genes may explain this variation in response to treatment. Pharmacogenetics and pharmacogenomics can facilitate more personalized medicine and prevent the adverse effects associated with treatment.
authors.affiliation: Service of Clinical Pharmacology, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria Princesa (IP), Diego de León 62, 28006 Madrid, Spain.
authors.forename: Rocío
authors.initials: R
authors.lastname: Prieto-Pérez
authors.forename: Teresa
authors.initials: T
authors.lastname: Cabaleiro
authors.forename: Esteban
authors.initials: E
authors.lastname: Daudén
authors.forename: Dolores
authors.initials: D
authors.lastname: Ochoa
authors.forename: Manuel
authors.initials: M
authors.lastname: Román
authors.forename: Francisco
authors.initials: F
authors.lastname: Abad-Santos
mesh_terms: D000287:Administration, Topical; D006801:Humans; D010597:Pharmacogenetics; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics*